Trial Profile

To evaluate the association between gonadotropin-releasing hormone (GnRH) agonists versus GnRH antagonist (Degarelix) and the risk of cardiovascular disease (CVD) in patients with prostate cancer with or without prior CVD.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Oct 2021 New trial record
13 Sep 2021 Results presented at the 116th Annual Meeting of the American Urological Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com